MCM
IKT icon

MAI Capital Management’s Inhibikase Therapeutics IKT Stock Holding History

MAI Capital Management’s Portfolio IKT Stock Details IKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$153 Buy
+91
New +$162 ﹤0.01% 4672

Other funds holding IKT

SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

MAI Capital Management's IKT Position: Q1 2026 in Review

MAI Capital Management opened a new position in Inhibikase Therapeutics (IKT) in Q1 2026: 91 shares worth $153. The stake represents ﹤0.01% of the portfolio and ranks #4672 among its holdings.

104 funds tracked by Wall St. Rank hold IKT as of Q1 2026.

  • MAI Capital Management held 91 shares of Inhibikase Therapeutics worth $153 as of Q1 2026.
  • Inhibikase Therapeutics was a new MAI Capital Management position in Q1 2026.
  • Inhibikase Therapeutics made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #4672 holding.
  • 104 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.